Drug Trial Radar · NCT05361005
Tolerability and Safety of BDB-001 Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Mar 12, 2020
Primary completion
May 8, 2020
Study completion May 8, 2020
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Beijing Defengrei Biotechnology Co.,Ltd
- First posted
- May 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.
Conditions
- Healthy
Interventions
BDB-001 injectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination AbnormalitiesTime frame: Up to 28 Days
- Maximum plasma concentration (Cmax)Time frame: Up to 504 hours postdose
- Area under the plasma concentration-time curve from time 0 to infinity (AUC0inf)Time frame: Up to 504 hours postdose
- Area under the plasma concentration-time curve from time 0 to 480hr(AUC00-480hr)Time frame: Up to 504 hours postdose
- Time of maximum concentration (Tmax)Time frame: Up to 504 hours postdose
- Elimination half-life (t1/2)Time frame: Up to 504 hours postdose
- Clearance (CL)Time frame: Up to 504 hours postdose
- Apparent volume of distribution (Vz)Time frame: Up to 504 hours postdose
- Mean residence time (MRT)Time frame: Up to 504 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shu Lan (Hangzhou) Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.